FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) — FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced the publication of a groundbreaking paper in the journal Science Advances detailing the development of CHIPS (Collagen-based High-resolution Internally Perfusable Scaffolds), a fully-biologic, 3D-bioprinted tissue platform engineered for internal perfusion and organ-level function. The work, led by Dr. Adam Feinberg and colleagues at Carnegie Mellon University, demonstrates the ability to fabricate centimeter-scale tissue constructs combining cells and extracellular matrix with unprecedented precision and functional fidelity.
This new CHIPS platform provides a crucial technological bridge between foundational FRESH™ 3D bioprinting capabilities and FluidForm Bio's therapeutic mission—to create vascularized tissue constructs that support the viability and function of implanted islet cells.
'CHIPS represent the next generation of tissue scaffolding,' said Andrew Hudson, PhD, Co-Founder of FluidForm Bio and co-author of the paper. 'They enable not just structure, but function—supporting dynamic perfusion, vascularization, and even glucose-stimulated insulin secretion in engineered tissue constructs. This is the kind of platform our therapeutic programs require.'
By combining native extracellular matrix components such as collagen and fibrin with vascular and endocrine cells—including insulin-secreting MIN6 beta-like cells—the study achieves a first: a fully-biologic, perfusable pancreatic-like tissue that responds to glucose and secretes insulin. Under perfusion, these constructs exhibited significant cell migration, vascular network formation, and insulin output, with a stimulation index beyond what is achieved with traditional biofabrication approaches.
'These results validate FRESH as the enabling technology not only for research but for our ongoing clinical translation,' said Adam Feinberg, PhD, who is also Co-Founder and Chief Technology Officer of FluidForm Bio. 'The constructs described in this paper are essentially blueprints for what we're building at FluidForm—fully cellularized, vascularized tissues for subcutaneous implantation and therapeutic function.'
The CHIPS paper adds momentum to FluidForm Bio's islet cell replacement therapy program, which leverages FRESH printing to create implantable tissue scaffolds that maintain islet health, support vascularization, and promote long-term glycemic control without the need for systemic immunosuppression. The company has demonstrated sustained normoglycemia in preclinical models for over five months using this approach.
The publication coincides with FluidForm Bio's live equity crowdfunding campaign on StartEngine, which invites supporters to participate in advancing the future of regenerative medicine.
The paper can be found online here: https://www.science.org/doi/10.1126/sciadv.adu5905
About FluidForm Bio™
FluidForm Bio™ is a biotechnology company developing next-generation cell therapies for chronic diseases leveraging its proprietary FRESH™ 3D bioprinting technology platform. Using FRESH, FluidForm creates functional tissue with the same materials found in the human body, eliminating chemistries and materials known to trigger negative immune response. FRESH is a powerful vascularization platform, allowing the building of densely cellular vascularized tissue that maintains viability upon implant.
The company's lead program is an islet cell therapy for type 1 diabetes in which insulin-producing beta cells are arranged in a tissue scaffold ready for subcutaneous implantation. This method is less invasive and less toxic when compared to other delivery sites, offering retrievability and reducing surgical risks and recovery time for patients.
This novel approach to islet cell replacement therapy presents a transformative advancement in diabetes treatment. With superior fabrication techniques, enhanced vascularization, a robust immune modulation platform, and a convenient subcutaneous implant, this method addresses many limitations of current technologies. These improvements offer the potential for a more effective, durable, and patient-friendly therapy, offering new hope for individuals with diabetes.
Founded in 2018, FluidForm is headquartered in Waltham, MA. To learn more, please visit: fluidformbio.com or connect on Twitter and LinkedIn.
Contact:Corey Davis, Ph.D.LifeSci Advisors+1 212 915 2577
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ('Jade') (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The findings, presented during an oral session at the 62nd European Renal Association (ERA) Congress, support advancement of JADE101 into a planned healthy volunteer study in the second half of 2025. 'IgA nephropathy often begins in young adulthood and typically requires lifelong treatment, yet current treatment options have limitations in efficacy and ease of use,' said Andrew King, BVMS, Ph.D., Chief Scientific Officer and Head of R&D at Jade Biosciences. 'Jade's preclinical data presented at ERA demonstrate JADE101's potential to be a best-in-class disease-modifying therapy. JADE101 has the potential to fully capture the efficacy available to the anti-APRIL mechanism with convenient, infrequent dosing. We believe this profile could translate into meaningful long-term benefit for patients, and we look forward to advancing this promising candidate into the clinic later this year.' Summary of Jade Biosciences' ERA 2025 Presentation Jade's presentation at ERA focused on a comprehensive preclinical characterization of JADE101, a fully human monoclonal antibody targeting APRIL, designed to address key limitations of earlier molecules in this class. JADE101 incorporates a YTE-modified IgG1 backbone and was engineered to improve target affinity, extend pharmacokinetic exposure, and reduce risks associated with immune complex formation and rapid clearance. The molecular design of JADE101 prolonged systemic exposure that delivers sustained target engagement, with a goal of supporting clinical dosing intervals of eight weeks or potentially longer. JADE101 was compared with sibeprenlimab, an investigational late-stage anti-APRIL monoclonal antibody, manufactured from publicly available sequences. A YTE-engineered version of sibeprenlimab was also tested to isolate the impact of Fc modification on pharmacokinetic profiles in non-human primates (NHPs). Key findings included: Ultra-high APRIL binding affinityJADE101 binds APRIL with femtomolar affinity (approximately 50 fM), over 750-fold higher affinity than sibeprenlimab. This higher binding affinity has the potential to enable complete suppression of APRIL at low plasma concentrations of JADE101 to deliver the full efficacy available to the anti-APRIL mechanism and further support an extended dosing interval. Potent inhibition of APRIL signaling through BCMA and TACIJADE101 demonstrated potent blockade of APRIL binding and signaling through its receptors in in vitro assays, including assays designed to model mechanistic aspects of the therapeutic benefit of APRIL inhibition in IgAN. In competitive binding assays, JADE101 fully inhibited APRIL binding to its receptors BCMA and TACI with IC50 values of 1.9 nM and 1.03 nM, respectively. In cell-based reporter assays, JADE101 blocked APRIL-induced signaling through BCMA (IC50 = 5.97 nM) and TACI (IC50 = 0.22 nM). JADE101 also potently reduced human plasma cell proliferation and IgA secretion in vitro. Extended pharmacokinetics and deep, sustained IgA suppression in NHPsIn NHPs, a single 30 mg/kg intravenous dose of JADE101 demonstrated an approximately 27-day half-life, nearly 4 times longer than sibeprenlimab at the same dose, and maintained linear clearance down to approximately 2 µg/mL, well below the approximately 40 µg/mL target-mediated drug disposition (TMDD) threshold observed for sibeprenlimab. This pharmacokinetic profile translated into sustained IgA suppression for more than 100 days after a single 30 mg/kg dose in NHPs. Notably, JADE101 dosed at just 4 mg/kg (7.5-fold lower) achieved deeper and more durable IgA reductions in NHPs than both sibeprenlimab and YTE-modified sibeprenlimab dosed at 30 mg/kg. Favorable subcutaneous profile in NHPsFollowing a single 100 mg/kg subcutaneous dose, JADE101 exhibited high bioavailability and a linear half-life exceeding 30 days in NHPs, supporting the potential for convenient, infrequent subcutaneous dosing in clinical settings. Designed to reduce risk of high molecular weight immune complex formationJADE101 binds a novel epitope on trimeric APRIL and was specifically selected to avoid the formation of high molecular weight immune complexes, that can occur with the first-generation anti-APRIL monoclonal antibodies. Immune complexes have potential to be associated with an increased risk of immunogenicity and tissue deposition, and to result in accelerated drug clearance. By avoiding their formation, JADE101 may mitigate these risks, supporting more consistent pharmacokinetics and sustained exposure over time. Jade plans to initiate a study of JADE101 in healthy volunteers in the second half of 2025. The study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and suppression of key biomarkers including APRIL and IgA. Interim data are expected in the first half of 2026 and are anticipated to guide dose and dose interval selection for future JADE101 studies in patients with IgAN. Conference Call and Webcast Jade Biosciences will host a conference call and webcast today, Monday, June 9, 2025, at 8:00 a.m. ET to review the JADE101 data presented at ERA 2025. Investors and the public are invited to join the live webcast by registering on the 'Events and Presentations' page of To join the conference call, participants must register here. Upon registering, dial-in details and a unique PIN will be provided. A replay of the webcast will be available shortly after the call concludes. About IgA nephropathy (IgAN) IgAN is a chronic autoimmune kidney disease that affects approximately 169,000 people in the U.S. and is most often diagnosed in young adults. The disease is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to increased protein in the urine, also known as proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or a transplant. IgAN often requires lifelong treatment to preserve kidney function and prevent progression to kidney failure. About JADE101 JADE101 is an anti-APRIL monoclonal antibody being developed for the treatment of IgAN. By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. Engineered with half-life extension technology, JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. About Jade Biosciences, Inc. Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit and follow the Company on LinkedIn. Forward-Looking Statements Certain statements in this communication, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade's expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade's ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and the JADE-003 program, including without limitation the expected timelines for JADE101 entering the clinic and interim data from such trial, the potential of Jade's product candidates to become best-in-class therapies and their potential therapeutic uses, efficacy, dosing, safety and market opportunities. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade's product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; risks associated with Jade's dependence on third-party vendors for the development, manufacture and supply of JADE101; and the other risks, uncertainties and factors more fully described in Jade's most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. Jade Biosciences Media & Investor Contacts Priyanka ShahEmail: Media@ Email: IR@ Phone: 908-447-6134Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance
Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology Enhanced cross-platform compatibility helps simplify device integration, increase longevity of capital equipment, reduce customization development time and lower costs The first of several Phillips Medisize–branded medical connectors planned to launch over the next 18–24 months, TheraVolt™ provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with Phillips Medisize's 60+ years of medical experience HUDSON, Wis., June 09, 2025--(BUSINESS WIRE)--Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of medtech, pharmaceutical drug delivery and in vitro diagnostic devices, announces the launch of TheraVolt™ Medical Connectors. As the first medical connectors launched under the Phillips Medisize brand, TheraVolt is engineered to optimize device integration, functionality, reliability and performance. TheraVolt provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines. Emerging trends in electrophysiology (EP), most notably the rapid adoption of pulsed field ablation (PFA) technology, are driving increased demand for advanced medical connectors that support higher pin count densities and compact design. With enhanced cross-platform compatibility, TheraVolt Medical Connectors help simplify medical device integration, increase longevity of capital equipment, reduce customization development time and lower costs. This can enable more efficient solutions and greater flexibility for medical device companies developing PFA treatment for patients living with atrial fibrillation. "With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers," said Pete Soupir, vice president, MedTech segment at Phillips Medisize. "TheraVolt Medical Connectors empower our medical device customers to develop next-gen EP devices with enhanced integration, connectivity and performance. Their high pin count and high voltage clearance is particularly valuable in medical devices used in electrophysiology treatments, with multiple therapy options, complex functions and expanded data collection." These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with more than 60 years of medical experience from Phillips Medisize. TheraVolt Medical Connectors support next-generation medical device integration and performance through: High Pin Count and Voltage Clearance: Enables the integration of more functionalities, allowing medical device engineers to design multi-therapy medical devices with expanded capabilities, advanced functions and increased data collection. Design Flexibility and Customization: Available off-the-shelf with the flexibility to be tailored to meet diverse application demands, with customizable configurations for specific pin counts and precise electrical requirements. Sterilization Compatibility: Engineered to withstand multiple autoclave cycles, maintaining integrity and performance even under repeated exposure to harsh sterilization processes. Safety and Reliability: Designed to support compliance with IEC and IPC requirements, helping to promote dependable operation in medical applications. Additional Phillips Medisize Medical Connectors are in development and will be delivered over the next 18–24 months. Learn more about TheraVolt Medical Connectors at and About Phillips Medisize Phillips Medisize, a Molex company, collaborates with leading medical technology, pharmaceutical and in vitro diagnostic companies to design, engineer and manufacture lifesaving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to collaborate with customers to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit About Molex Molex is a global electronics leader committed to making the world a better, more-connected place. With a presence in more than 38 countries, Molex enables transformative technology innovation in the consumer device, aerospace and defense, data center, cloud, telecommunications, transportation, industrial automation, and healthcare industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit View source version on Contacts Media Contact: Merryman CommunicationsHelen Winklerhelen@
Yahoo
33 minutes ago
- Yahoo
TYBR Health Announces FDA 510(k) Clearance for B3 GEL™ System, a Flowable Bio-Gel to Protect Healing Tissue and Preserve Function
HOUSTON, June 9, 2025 /PRNewswire/ -- TYBR Health, a medical device and regenerative medicine company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the B3 GEL™ System. B3 GEL™ is a bioresorbable, flowable gel barrier designed to protect healing tissue planes and preserve mobility following surgeries involving tendons, ligaments, and skeletal muscle. This clearance marks a significant milestone for TYBR Health, enabling a new approach to support functional recovery in musculoskeletal surgery. B3 GEL™ helps maintain surgical precision by temporarily separating tissues during the early healing phase—without impeding the natural healing process. "When we started TYBR, it was with a clear purpose: to solve a real, overlooked problem in surgical recovery," said Tim Keane, PhD, Cofounder and CEO of TYBR Health. "Too often, healing goes unprotected once the procedure ends. B3 GEL™ is designed to fill that gap—working with the body's biology to protect tissue planes and give surgeons a way to safeguard patient outcomes during the critical early phase of recovery." B3 GEL™ is composed of a naturally derived extracellular matrix and is applied via TYBR's proprietary integrated mixer-applicator system. Its flowable format conforms to complex anatomy and can be used in both open and minimally invasive procedures. The blue-colored gel allows for visual confirmation of placement and resorbs completely over time without leaving residual bulk. Preclinical studies submitted to support clearance demonstrated that B3 GEL™ reduced tissue binding and supported improved range of motion in treated models, with enhanced flexion and extension compared to controls (data on file). TYBR Health plans to begin commercial sales of the B3 GEL™ System by the end of 2025. About TYBR HealthFounded in 2020, TYBR Health is a medical device and regenerative medicine company focused on improving surgical recovery. Headquartered in Houston, Texas, TYBR develops solutions that help surgeons protect healing tissues and preserve function after surgery. Its lead product, the B3 GEL™ System, is a bioresorbable gel barrier cleared by the FDA to aid in the protection of soft tissues during post-surgical healing. TYBR is targeting a significant unmet need in musculoskeletal surgery, where recovery complications impact function and healthcare costs. With FDA clearance secured, manufacturing in place, and a proprietary delivery system developed for precise, intraoperative use, TYBR is preparing for commercial launch in late 2025. For more information contact: info@ View original content to download multimedia: SOURCE TYBR Health
